USA flag logo/image

An Official Website of the United States Government

An Automated Platform for High-throughput Network Electrophysiology

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R44NS062477
Solicitation Year:
2013
Solicitation Topic Code:
NINDS
Solicitation Number:
PA11-135
Small Business Information
AXION BIOSYSTEMS, LLC
311 Ferst Drive ATLANTA, GA 30332-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: An Automated Platform for High-throughput Network Electrophysiology
Agency: HHS
Contract: 2R44NS062477-06
Award Amount: $2,079,865.00
 

Abstract:

DESCRIPTION (provided by applicant): In response to the program announcement for Phase IIb proposals for complex, in-vitro brain and behavior tools (PA-11-135), this proposed study automates all aspects of in-vitro Microelectrode Array (MEA) technology todeliver the first ever high throughput MEA-based screening system. This development will not only enable rapid advancements in the study of basic network-level electrophysiology, but it will also create new opportunities for CNS disease modeling and phenotypic screening. This Phase IIb proposal involves two significant developments for neurological research, both building on the commercialized 768-channel multiwell MEA system developed in Phase II. Specifically, Aim 1 automates compound administration and experiment management to produce a turnkey platform for dosing neural culture as well as capturing, com- pressing, and storing network electrophysiological datasets. Among its many advantages, this platform will recover signals traditionally obscured by stimulation artifacts. This capability, combined with the ability to simultaneously manage 768 microelectrodes and automate experimental protocols, will capture single-cell and network-level neural activity at unparalleled rates. In addition, Aim 2 will automate the analysis of the immense volumes of continuous, data traces generated by the Aim 1 developments, translating massive raw datasets into meaningful metrics that accurately reflect the interactions between networks of cells. Ultimately, the final MEA screening platform will provide automated liquid handling, user-friendly experiment tools, and sophisticated neural analysis software. For scientists, this integration will significantly improve their ability to extact functional information from neural cultures; paving the way for new progress in drug discovery, safety assessment, and basic science. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This research uses novel software analysis tools and automated liquid handlers to create faster, lower-cost methods for neural research. Ultimately, this development will facilitate medical and scientific discoveries that will benefit the treatmentof neural disorders such as Parkinson's disease and epilepsy.

Principal Investigator:

James Ross
404-218-3527
jross@axionbio.com

Business Contact:

James Ross
404-218-3527
jross@axionbio.com
Small Business Information at Submission:

AXION BIOSYSTEMS, LLC
311 Ferst Drive ATLANTA, GA 30332-

EIN/Tax ID: 130047234
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No